GPA33 Recombinant Monoclonal Antibody

GPA33, also known as glycoprotein A33, is a transmembrane protein predominantly expressed in normal intestinal epithelium and maintained in over 95% of colorectal carcinomas. This restricted expression pattern, combined with its stable presence on the cell surface of malignant cells, has established GPA33 as a compelling target for colorectal cancer research and therapeutic antibody development. Understanding GPA33 expression and localization provides valuable insights into intestinal biology and colorectal cancer progression.

This recombinant monoclonal antibody, clone 4H4, offers the reproducibility and consistency that demanding research applications require. Generated against a synthetic peptide derived from human GPA33 and produced using recombinant technology, this antibody delivers sequence-defined specificity with minimal lot-to-lot variation. For researchers conducting longitudinal studies or multi-site collaborations, this consistency translates directly into comparable results across experiments and reduced time spent on antibody re-optimization.

Validation studies demonstrate reliable performance in immunohistochemistry applications on human tissues. Testing on paraffin-embedded human small intestine tissue confirms detection of GPA33 in its expected physiological context, while staining of human colon cancer tissue validates utility in oncology research settings. Both applications performed optimally at 1:100 dilution using citrate buffer antigen retrieval, providing a solid starting point for your experimental optimization.

The antibody is supplied in a glycerol-containing buffer formulation designed for long-term stability at -20°C or -80°C, supporting extended research programs. Whether you are investigating intestinal epithelial biology, characterizing colorectal tumor samples, or evaluating GPA33 as a therapeutic target, this recombinant antibody provides the specificity and consistency essential for meaningful immunological and cancer research outcomes.